Cardio3 BioSciences (CARD)

Business description

Cardio3 is developing C-Cure - an autologous Ph III stem cell therapy for chronic IHD. An innovative cell cancer CAR-T therapy, NKG2D, was acquired in 2015. It is also developing high-value cardiac devices: Cathez and CorQuest.

Share price chart

Share chart

Stock data

Market cap.€350.8m
Last close€45.30
High / Low (52 weeks)€47.0 / €30.1
Stock market listingEU
Forecast net debt (€m)6.1
Forecast gearing ratio (%)137
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(0.8)37.011.7
Relative *(0.5)22.3(6.7)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Carmat
Celldex Therapeutics Cellectis
Cerulean Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

BRIEF-Cardio3 Biosciences FY net loss rises to 16.6 mln euros

Thu, 26 Mar 2015 06:33:45 GMT

Cardio3 BioSciences Reports 2014 Financial and Operating Results

Thu, 26 Mar 2015 10:07:30 GMT

BRIEF-Cardio3 Biosciences announces opening of new production facility in ...

Mon, 23 Mar 2015 06:07:46 GMT

BRIEF-Cardio3 Biosciences buys OnCyte CAR T-Cell portfolio from Celdara ...

Tue, 06 Jan 2015 06:22:30 GMT

Cardio3 Biosciences to Address American Institutional Investors in January at ...

Mon, 15 Dec 2014 13:52:30 GMT

Investment summary

Cardio3’s C-Cure Phase III autologous stem cell therapy aims to regenerate damaged heart muscle. CHART-1 Phase III data are possible in H116. In cancer, Cardio3 is now active in CAR-T therapy after the $10m January 2015 OnCyte acquisition. The planned Phase I/II haematological study is expected to report in 2016. In cardiac surgery, Cardio3 acquired a virtual US cardiac surgical company, CorQuest. The main product is an innovative device to repair mitral valves, which may gain a CE mark by late 2016. Cash at 30 June was €40.1m with a six-month loss of €5.9m.

Last updated on 02/03/2015

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2012A 0.1 (7.9) (8.8) (724.37) N/A N/A
2013A 0.0 (9.8) (10.4) (253.22) N/A N/A
2014E 0.0 (9.4) (9.4) (145.44) N/A N/A
2015E 0.0 (7.1) (7.0) (107.62) N/A N/A

Last updated on 24/02/2015

Latest research

Latest video

Analyst Interview – Cardio3 BioSciences

Industry outlook

In stem cells, CHART-2 (Phase III, FDA approved) may start by mid 2015 after the CHART-1 futility analysis. Medisun may invest €20m extra in Chinese clinical development. Teva's Phase III study could produce data in 2018. Cytori ended a Phase II; Capricor is in Phase II. Novartis, Juno and Kite are active in the CAR-T cancer therapies area; the Cardio3 NKG2D approach may apply to ovarian cancer and allow allogeneic therapy.

Last updated on 02/03/2015

Key management

Michel Lussier, Chairman
Dr Christian Homsy, CEO
Patrick Jeanmart, CFO
Dr Gaëtane Metz, COO

Company address

Rue Edouard Belin 12
1435 Mont-Saint-Guibert
Belgium
+32(0)10 39 41 00
View website